AP26113 is an analog of AP26113 which is a potent and selective ALK inhibitor. It is also an inhibitor of EGFR.

CNX-2006 is an irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.

BI-4020 is a noncovalent, new-generation, wild-type EGFR sparing, macrocyclic tyrosine kinase inhibitor.

TQB3804 is the forth-generation EGFR inhibitor with IC50 values of 7.92nM,0.218nM and 0.16nM for EGFR(WT), EGFR (C797S/T790M/del19) and EGFR (L858R/T790M/C797S), respectively.

Zipalertinib是一种新型的 EGFR 突变抑制剂，专门针对肿瘤中存在的特定 EGFR 突变。它在治疗各种 EGFR 突变相关癌症，如非小细胞肺癌等方面具有显著潜力。

Avitinib selectively inhibits EGFR L858R/T790M mutant with IC50 of 7.68 nM. It used as antineoplastic drug candidate.

Lazertinib is a selective inhibitor of mutant EGFR with lowest activity against EGFR wild type.

In vitro, BGB-283 potently inhibits BRAFV600E-activated ERK phosphorylation and cell proliferation.

EGF816 inhibits mutant EGFR (L858R/790M) with Ki of 31 nM irreversibly and selectively.

Brigatinib is a selective ALK inhibitor with IC50 value of 0.37nM, and also inhibits ROS1, FLT3, FLT3-D835Y mutant and EGFR less potently.

AV-412 是一种有效的 EGFR 和 ErbB2 (IC50=19 nM) 酪氨酸激酶的双重抑制剂，包括突变型 EGFR (L858R IC50=0.51 nM, T790M IC50=0.79 nM)。它抑制 EGFR 和 ErbB2 的自磷酸化，IC(50) 分别为 43 nM 和 282 nM。

HS-10296 is the third-generation EGFR TKIs which exhibited inhibitory effect on both EGFR-activating mutations and T790M-resistant mutation.

EAI045, an allosteric inhibitor, selectively targets drug-resistant EGFR mutants like EGFR-L858R, EGFR-T790M and EGFR-L858R/T790M with IC50 of 0.019 μM, 0.19 μM and 0.002 μM respectively.

JND3229 is a new highly potent EGFR(C797S) inhibitor with IC50 values of 5.8nM, 30.5nM and 6.8nM for EGFR (L858R/T790M/C797S), EGFR (T790M, L858R) and EGFR, respectively.

Gefitinib（ZD1839）是一种强效、选择性和口服活性的EGFR酪氨酸激酶抑制剂。

Theliatinib, is a small molecule, epidermal growth factor receptor tyrosine kinase inhibitor with potential antineoplastic and anti-angiogenesis activities.